目的 探讨术前负荷剂量重组人脑利钠肽(recombinant human brain natriuretic peptide,rhBNP)对行急诊经皮冠状动脉介入(PCI)治疗的急性前壁心肌梗死患者冠脉无复流的干预作用。方法 序贯入选80例在武警天津总队医院行急诊PCI治疗的急性前壁心肌梗死患者,随机分为治疗组和对照组。治疗组PCI术前在常规药物治疗的基础上以1.5 μg/kg负荷剂量静推rhBNP;对照组单纯给予常规药物治疗;比较两组患者PCI术中冠脉无复流的发生情况。结果 治疗组在给药后冠脉无复流(2.5% vs 15.0%)及再灌注心律失常的比例明显低于对照组,差异有统计学意义。rhBNP相关的严重不良反应比较,两组住院期间主要心血管事件发生率无明显差异。结论 急性前壁心肌梗死患者急诊PCI术前应用负荷剂量rhBNP可显著改善冠脉血流,减少再灌注心律失常的发生。
Abstract
Objective To investigate the effect of bolus intravenous injection of recombinant human brain natriuretic peptide (rhBNP) before primary percutaneous coronary intervention (PCI) on coronary no-reflow in patients with anterior wall acute myocardial infarction (AMI).Methods Eighty consecutive patients with anterior wall AMI after Primary PCI were randomly divided into therapy group(n=40) and control group(n=40). Patients in therapy group were treated with bolus intravenous injection of rhBNP (1.5 μg/kg). Both the control and the therapy group received conventional treatment. The neuroendocrine hormone level, inflammatory factor level and ventricular function were measured upon admission and 7 days later. The incidence of coronary no-reflow in both groups was observed during PCI.Results The incidence of coronary no-reflow and reperfusion arrhythmia in therapy group markedly decreased compared with control group (P＜0.05). No adverse events during drug infusion were observed and MACE during hospitalization was also similar in both groups.Conclusions Patients with anterior wall AMI before primary PCI treated with bolus intravenous injection of rhBNP can markedly decrease the coronary no-reflow and reperfusion arrhythmia.
关键词
重组人脑利钠肽 /
冠状动脉介入治疗 /
急性前壁心肌梗死 /
无复流
Key words
recombinant human brain natriuretic peptide /
percutaneous coronary intervention /
anterior wall acute myocardial infarction /
no-reflow
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] Fox KA,Steg PG,Eagle KA, et al. Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006[J]. Jama, 2007, 297 (17): 1892-1900.
[2] 刘 庆. 尿酸对急性心肌梗死急诊PCI术后患者近期预后的影响[J]. 武警医学, 2016,27(10):990-993.
[3] 杨国红,王 伟.AMI患者急诊PCI术后无复流现象的相关因素及近期预后[J]. 天津医科大学学报,2008,14(4):568-570.
[4] Li J W,Chen Y D,Chen W R, et al. Plasma DPP4 activity is associated with no-reflow and major bleeding events in Chinese PCI-treated STEMI patients[J]. Scientific reports, 2016, 6:39412.
[5] Arslan U,Yaman M,Kocaoglu I, et al. Risk of no-reflow in culprit lesion versus culprit vessel PCI in acute STEMI[J]. Coronary Artery Disease, 2015,26(6):510-515.
[6] 罗建平,刘惠亮. 维拉帕米治疗急性心肌梗死直接经皮冠状动脉介入术中无复流疗效的观察[J]. 武警医学, 2008, 19 (5): 441-444.
[7] Wang S,Qu X,Qu Y, et al. The effect of B-type brain natriuretic peptide on patients with acute decompensated heart failure coexisting with lung cancer: a randomized controlled clinical trial[J]. Die Pharmazie, 2014, 69 (3): 212-216.
[8] Naffaa M,Makhoul B F,Tobia A, et al. Brain natriuretic peptide at discharge as a predictor of 6-month mortality in acute decompensated heart failure[J]. Am J Emer Med, 2014, 32 (1): 44-49.
[9] 付 尧,白子清. 重组脑利钠肽治疗慢性心力衰竭对醛固酮及内皮素-1的影响[J]. 中国循环杂志, 2007, 22 (1): 18-21.
[10] Kasama S,Furuya M,Toyama T, et al. Effect of atrial natriuretic peptide on left ventricular remodelling in patients with acute myocardial infarction[J]. Euro heart J, 2008,29(12):1485-1494.
PDF(488 KB)
